Analyst Price Target is $44.18
▲ +3,196.64% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for 9 Meters Biopharma in the last 3 months. The average price target is $44.18, with a high forecast of $100.00 and a low forecast of $1.70. The average price target represents a 3,196.64% upside from the last price of $1.34.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in 9 Meters Biopharma. This rating has held steady since August 2022, when it changed from a Hold consensus rating.
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.